Aprea Therapeutics, Inc. (APRE)
APRE Stock Price Chart
Explore Aprea Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze APRE price movements and trends.
APRE Company Profile
Discover essential business fundamentals and corporate details for Aprea Therapeutics, Inc. (APRE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Oct 2019
Employees
8.00
Website
https://atrinpharma.comCEO
Oren Gilad
Description
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
APRE Financial Timeline
Browse a chronological timeline of Aprea Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
APRE Stock Performance
Access detailed APRE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
